Kimmie Ng

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer
    Shoko Kure
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:2765-72. 2009
  2. ncbi Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741
    Kimmie Ng
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 29:1599-606. 2011
  3. ncbi Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803
    Kimmie Ng
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:4354-63. 2010
  4. ncbi Adjuvant and neoadjuvant approaches in gastric cancer
    Kimmie Ng
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer J 13:168-74. 2007
  5. ncbi Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803
    Kimmie Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Natl Cancer Inst 103:1540-51. 2011
  6. ncbi Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer
    Kimmie Ng
    Division of Medical Oncology, Dana Farber Cancer Institute Boston, MA 02115, USA
    J Clin Oncol 26:2984-91. 2008
  7. ncbi Reported behavior of eating anything at anytime and risk of colorectal cancer in women
    Ying Bao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Int J Cancer 130:1395-400. 2012
  8. ncbi Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:890-900. 2012
  9. ncbi Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:176-85. 2009
  10. ncbi Interaction of molecular markers and physical activity on mortality in patients with colon cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5931-6. 2009

Detail Information

Publications24

  1. ncbi Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer
    Shoko Kure
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:2765-72. 2009
    ..Our data support potential interactions between the VDR, RAS-MAPK and PI3K-AKT pathways, and possible influence by KRAS or PIK3CA mutation on therapy or chemoprevention targeting VDR...
  2. ncbi Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741
    Kimmie Ng
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 29:1599-606. 2011
    ....
  3. ncbi Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803
    Kimmie Ng
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:4354-63. 2010
    ..Multivitamin use is widespread in the United States, especially among patients with cancer. However, the influence of multivitamin supplementation on cancer recurrence and death after a curative resection of colon cancer is unknown...
  4. ncbi Adjuvant and neoadjuvant approaches in gastric cancer
    Kimmie Ng
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer J 13:168-74. 2007
    ....
  5. ncbi Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803
    Kimmie Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Natl Cancer Inst 103:1540-51. 2011
    ..Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown...
  6. ncbi Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer
    Kimmie Ng
    Division of Medical Oncology, Dana Farber Cancer Institute Boston, MA 02115, USA
    J Clin Oncol 26:2984-91. 2008
    ..Higher plasma 25-hydroxyvitamin D(3) (25(OH)D) levels are associated with a decreased incidence of colorectal cancer, but the influence of plasma 25(OH)D on the outcome of patients with established colorectal cancer is unknown...
  7. ncbi Reported behavior of eating anything at anytime and risk of colorectal cancer in women
    Ying Bao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Int J Cancer 130:1395-400. 2012
    ..05). In conclusion, reports of eating anything at anytime are associated with an increased risk of colorectal cancer in this large prospective cohort study, independent of other potential risk factors for colorectal cancer...
  8. ncbi Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:890-900. 2012
    ..irinotecan (CPT11), FU and LV (IFL); CALGB 89803]. Cox proportional hazards model was used to assess the prognostic role of BRAF mutation, adjusting for clinical features, adjuvant chemotherapy arm, and MSI status...
  9. ncbi Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:176-85. 2009
    ..Excess energy balance leads to increased circulating insulin and depressed levels of circulating insulin-like growth factor binding protein (IGFBP) -1, which promote cancer cell growth in preclinical models...
  10. ncbi Interaction of molecular markers and physical activity on mortality in patients with colon cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5931-6. 2009
    ..Physical activity in colon cancer survivors has been associated with lower cancer recurrences and improved survival. Whether molecular features of the tumor portend more or less likelihood for benefit from exercise is unknown...
  11. ncbi PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype
    Yoshifumi Baba
    Department of Medical Oncology, Dana FarberCancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Cancer Epidemiol Biomarkers Prev 19:822-31. 2010
    ..However, the prognostic significance of PTGER2 expression or its relationship with MSI, CIMP, LINE-1 hypomethylation, or PTGS2 (COX-2) remains uncertain...
  12. ncbi Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 18:377-8. 2013
    ..2% vs. 29.4%) and longer OS times (10.6 vs. 3.7 months). Conclusions. The oral combination of tivozanib and everolimus was well tolerated, with stable disease achieved in 50% of patients with refractory, metastatic colorectal cancer...
  13. ncbi Plasma 25-hydroxyvitamin D and risk of pancreatic cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Cancer Epidemiol Biomarkers Prev 21:82-91. 2012
    ..Laboratory studies suggest that vitamin D may inhibit pancreatic cancer cell growth. However, epidemiologic studies of vitamin D and pancreatic cancer risk have been conflicting...
  14. ncbi Dietary insulin load, dietary insulin index, and colorectal cancer
    Ying Bao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 19:3020-6. 2010
    ..On the basis of a novel insulin index for individual foods, we estimated insulin demand for overall diets and assessed its association with colorectal cancer in the Nurses' Health Study and Health Professionals Follow-up Study...
  15. ncbi Prediagnostic plasma folate and the risk of death in patients with colorectal cancer
    Brian M Wolpin
    Department of MedicalOncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 26:3222-8. 2008
    ..Therefore, high priority has been given to research investigating the influence of folate on cancer progression in patients with colorectal cancer...
  16. ncbi Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA
    Cancer Res 73:1600-10. 2013
    ..Furthermore, they suggest that energy balance and metabolism status exerts its effect in a specific carcinogenesis pathway that is less likely dependent on WNT/CTNNB1 activation...
  17. ncbi A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
    Jason E Faris
    Department of Medical Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USA
    Invest New Drugs 30:1614-20. 2012
    ..MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin-β family. We conducted an open-label Phase II study with MKC-1 in patients with advanced pancreatic cancer...
  18. ncbi Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies
    Jung Eun Lee
    Department of Food and Nutrition, Sookmyung Women s University, Seoul, Korea
    Cancer Prev Res (Phila) 4:1808-15. 2011
    ..Current statin use was not associated with risk of overall colorectal cancer. The possibility that statin use may be associated with lower risk of rectal cancer or KRAS wild-type colorectal cancer requires further confirmation...
  19. ncbi Effect of vitamin D supplementation on blood pressure in blacks
    John P Forman
    Renal Division and Kidney Clinical Research Institute, Brigham and Women s Hospital, 41 Ave Louis Pasteur, Suite 120, Boston, MA 02115, USA
    Hypertension 61:779-85. 2013
    ....
  20. ncbi Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy
    Nadine J McCleary
    Dana Farber Cancer Institute, Department of Medical Oncology, Gastrointestinal Oncology, 450 Brookline Avenue, Boston, MA 02215, USA
    Oncologist 18:64-72. 2013
    ..The Cancer-Specific Geriatric Assessment (CSGA) is a primarily self-administered paper survey of validated measures...
  21. ncbi Targeting the epidermal growth factor receptor in metastatic colorectal cancer
    Kimmie Ng
    Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA
    Crit Rev Oncol Hematol 65:8-20. 2008
    ..Novel strategies of targeting the EGFR pathway to improve efficacy, as well as ongoing research in identifying molecular predictors of response to anti-EGFR agents, will also be reviewed...
  22. ncbi Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
    Michael S Gordon
    Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
    J Clin Oncol 24:4324-32. 2006
    ..CONCLUSION: Pertuzumab is well tolerated with a RR of 4.3% in heavily-pretreated OC patients. Further studies on pHER2 as a diagnostic are warranted...
  23. ncbi Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
    David B Agus
    Cedars Sinai Prostate Cancer Center, Los Angeles, CA 90048, USA
    J Clin Oncol 25:675-81. 2007
    ..The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC) patients who had experienced progression after prior chemotherapy...
  24. ncbi Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy
    James D Lewis
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 423 Guardian Dr, Seventh Floor Blockley Hall, Philadelphia, PA 19104 6021, USA
    Arch Intern Med 163:413-20. 2003
    ..To address this, we performed a systematic review and meta-analysis of screening colonoscopy studies...